| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 109 | 2025 | 278 | 22.950 |
Why?
|
| Solitary Pulmonary Nodule | 35 | 2025 | 40 | 9.360 |
Why?
|
| Tomography, X-Ray Computed | 51 | 2025 | 215 | 8.770 |
Why?
|
| Early Detection of Cancer | 35 | 2025 | 559 | 5.730 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 24 | 2022 | 54 | 5.150 |
Why?
|
| Humans | 239 | 2026 | 17622 | 4.540 |
Why?
|
| Multiple Pulmonary Nodules | 12 | 2025 | 18 | 4.110 |
Why?
|
| Practice Guidelines as Topic | 24 | 2025 | 319 | 3.810 |
Why?
|
| Mass Screening | 22 | 2025 | 693 | 2.990 |
Why?
|
| Neoplasm Staging | 31 | 2022 | 350 | 2.750 |
Why?
|
| Male | 109 | 2026 | 10014 | 2.610 |
Why?
|
| Female | 116 | 2026 | 12715 | 2.600 |
Why?
|
| Venous Thromboembolism | 11 | 2026 | 55 | 2.540 |
Why?
|
| Guideline Adherence | 12 | 2025 | 155 | 2.450 |
Why?
|
| Aged | 76 | 2026 | 6223 | 2.420 |
Why?
|
| Postoperative Complications | 8 | 2026 | 99 | 2.420 |
Why?
|
| Positron-Emission Tomography | 18 | 2017 | 32 | 2.390 |
Why?
|
| Middle Aged | 83 | 2026 | 7954 | 2.310 |
Why?
|
| Retrospective Studies | 39 | 2026 | 2502 | 2.270 |
Why?
|
| Lung | 11 | 2023 | 57 | 2.250 |
Why?
|
| Emergency Service, Hospital | 10 | 2020 | 402 | 2.160 |
Why?
|
| Evidence-Based Medicine | 16 | 2016 | 173 | 2.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 11 | 2026 | 184 | 2.090 |
Why?
|
| Practice Patterns, Physicians' | 9 | 2025 | 308 | 2.040 |
Why?
|
| Smoking | 13 | 2026 | 420 | 2.030 |
Why?
|
| Anti-Bacterial Agents | 8 | 2020 | 152 | 1.830 |
Why?
|
| Societies, Medical | 17 | 2023 | 71 | 1.740 |
Why?
|
| United States | 47 | 2025 | 3922 | 1.740 |
Why?
|
| Watchful Waiting | 4 | 2025 | 22 | 1.730 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 1005 | 1.670 |
Why?
|
| Risk Assessment | 25 | 2020 | 1093 | 1.650 |
Why?
|
| Sinusitis | 4 | 2017 | 18 | 1.640 |
Why?
|
| Adenocarcinoma | 6 | 2016 | 172 | 1.570 |
Why?
|
| Pulmonary Medicine | 6 | 2019 | 19 | 1.520 |
Why?
|
| Diagnostic Imaging | 7 | 2020 | 42 | 1.470 |
Why?
|
| Critical Illness | 8 | 2022 | 53 | 1.470 |
Why?
|
| Pulmonary Embolism | 11 | 2020 | 46 | 1.430 |
Why?
|
| Delivery of Health Care, Integrated | 8 | 2026 | 540 | 1.400 |
Why?
|
| Hospitalization | 8 | 2024 | 831 | 1.350 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2017 | 56 | 1.290 |
Why?
|
| Hospital Mortality | 6 | 2022 | 135 | 1.260 |
Why?
|
| Radiation Dosage | 6 | 2025 | 16 | 1.220 |
Why?
|
| Fibrinolytic Agents | 8 | 2017 | 45 | 1.200 |
Why?
|
| Unnecessary Procedures | 6 | 2019 | 21 | 1.180 |
Why?
|
| Aged, 80 and over | 27 | 2026 | 1976 | 1.180 |
Why?
|
| Fluorodeoxyglucose F18 | 9 | 2016 | 12 | 1.180 |
Why?
|
| Venous Thrombosis | 7 | 2017 | 23 | 1.150 |
Why?
|
| Radiologists | 2 | 2025 | 6 | 1.110 |
Why?
|
| Patient Selection | 8 | 2024 | 181 | 1.100 |
Why?
|
| Risk Factors | 30 | 2026 | 3291 | 1.080 |
Why?
|
| Pulmonary Fibrosis | 6 | 2008 | 10 | 1.080 |
Why?
|
| Outcome Assessment (Health Care) | 10 | 2018 | 213 | 1.070 |
Why?
|
| Pandemics | 6 | 2022 | 295 | 1.040 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 148 | 1.020 |
Why?
|
| Decision Support Techniques | 6 | 2013 | 88 | 1.010 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2022 | 67 | 1.000 |
Why?
|
| Critical Care | 7 | 2023 | 64 | 1.000 |
Why?
|
| Incidental Findings | 6 | 2025 | 28 | 0.980 |
Why?
|
| Prognosis | 17 | 2020 | 609 | 0.970 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2026 | 7 | 0.970 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2026 | 9 | 0.970 |
Why?
|
| Surveys and Questionnaires | 18 | 2025 | 1296 | 0.950 |
Why?
|
| Quality Assurance, Health Care | 5 | 2014 | 120 | 0.930 |
Why?
|
| Referral and Consultation | 2 | 2022 | 161 | 0.920 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 49 | 0.910 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 56 | 0.900 |
Why?
|
| Predictive Value of Tests | 14 | 2023 | 346 | 0.900 |
Why?
|
| Heart Defects, Congenital | 2 | 2024 | 18 | 0.890 |
Why?
|
| Depression | 6 | 2023 | 507 | 0.890 |
Why?
|
| Quality of Life | 11 | 2019 | 505 | 0.880 |
Why?
|
| Adult | 43 | 2025 | 7621 | 0.870 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 17 | 0.870 |
Why?
|
| Fontan Procedure | 1 | 2024 | 3 | 0.860 |
Why?
|
| Follow-Up Studies | 15 | 2025 | 1157 | 0.850 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 2 | 2022 | 11 | 0.840 |
Why?
|
| Quality of Health Care | 4 | 2018 | 260 | 0.830 |
Why?
|
| Tomography, Emission-Computed | 6 | 2003 | 6 | 0.800 |
Why?
|
| Anticoagulants | 9 | 2022 | 125 | 0.800 |
Why?
|
| Lung Diseases | 7 | 2016 | 40 | 0.800 |
Why?
|
| Pneumonia | 3 | 2019 | 48 | 0.800 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 11 | 0.790 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 16 | 0.780 |
Why?
|
| Veterans | 5 | 2022 | 149 | 0.780 |
Why?
|
| Treatment Outcome | 20 | 2020 | 1161 | 0.770 |
Why?
|
| Lymph Nodes | 3 | 2017 | 17 | 0.760 |
Why?
|
| Patient Readmission | 2 | 2014 | 163 | 0.750 |
Why?
|
| Heparin | 7 | 2014 | 9 | 0.750 |
Why?
|
| Sensitivity and Specificity | 19 | 2016 | 302 | 0.740 |
Why?
|
| Radiography, Thoracic | 9 | 2020 | 18 | 0.740 |
Why?
|
| Betacoronavirus | 3 | 2020 | 36 | 0.710 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 29 | 0.710 |
Why?
|
| Severity of Illness Index | 6 | 2026 | 446 | 0.700 |
Why?
|
| California | 16 | 2025 | 2433 | 0.690 |
Why?
|
| Radiopharmaceuticals | 9 | 2016 | 13 | 0.690 |
Why?
|
| Prospective Studies | 16 | 2017 | 1251 | 0.690 |
Why?
|
| Exercise Therapy | 4 | 2019 | 75 | 0.690 |
Why?
|
| Probability | 7 | 2022 | 70 | 0.690 |
Why?
|
| Community Health Services | 1 | 2022 | 78 | 0.680 |
Why?
|
| Catheterization, Central Venous | 2 | 2016 | 10 | 0.680 |
Why?
|
| Clinical Competence | 4 | 2017 | 108 | 0.670 |
Why?
|
| Mediastinal Neoplasms | 3 | 2006 | 3 | 0.670 |
Why?
|
| Medical Overuse | 2 | 2018 | 14 | 0.670 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 27 | 0.670 |
Why?
|
| Decision Making | 6 | 2022 | 177 | 0.650 |
Why?
|
| Algorithms | 7 | 2012 | 227 | 0.650 |
Why?
|
| Cytokines | 1 | 2020 | 30 | 0.640 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 7 | 0.630 |
Why?
|
| Intensive Care Units | 8 | 2022 | 105 | 0.630 |
Why?
|
| Comorbidity | 10 | 2026 | 552 | 0.630 |
Why?
|
| Thrombolytic Therapy | 3 | 2009 | 19 | 0.610 |
Why?
|
| Time Factors | 11 | 2015 | 1038 | 0.610 |
Why?
|
| Heparin, Low-Molecular-Weight | 6 | 2017 | 10 | 0.600 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 12 | 0.600 |
Why?
|
| Patient Discharge | 3 | 2016 | 154 | 0.590 |
Why?
|
| Lymphatic Metastasis | 4 | 2017 | 30 | 0.590 |
Why?
|
| Bronchoscopy | 5 | 2017 | 9 | 0.580 |
Why?
|
| Hypertension, Pulmonary | 3 | 2009 | 6 | 0.570 |
Why?
|
| Survival Rate | 10 | 2016 | 252 | 0.560 |
Why?
|
| Natural Language Processing | 2 | 2025 | 60 | 0.560 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2016 | 25 | 0.560 |
Why?
|
| Outcome and Process Assessment (Health Care) | 4 | 2017 | 96 | 0.560 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2025 | 135 | 0.550 |
Why?
|
| Cost-Benefit Analysis | 12 | 2017 | 237 | 0.550 |
Why?
|
| Papillomavirus Infections | 3 | 2025 | 144 | 0.550 |
Why?
|
| Endosonography | 3 | 2017 | 9 | 0.540 |
Why?
|
| Education, Continuing | 1 | 2017 | 5 | 0.540 |
Why?
|
| Antimicrobial Stewardship | 1 | 2017 | 6 | 0.540 |
Why?
|
| Diagnosis, Differential | 11 | 2014 | 55 | 0.540 |
Why?
|
| Hemorrhage | 9 | 2020 | 62 | 0.530 |
Why?
|
| Population Surveillance | 2 | 2016 | 248 | 0.530 |
Why?
|
| Mediastinum | 1 | 2017 | 1 | 0.530 |
Why?
|
| Craniocerebral Trauma | 1 | 2017 | 12 | 0.530 |
Why?
|
| Electronic Health Records | 8 | 2025 | 719 | 0.520 |
Why?
|
| Sleep Wake Disorders | 3 | 2016 | 33 | 0.520 |
Why?
|
| Cohort Studies | 13 | 2025 | 2502 | 0.520 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 33 | 0.520 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 193 | 0.510 |
Why?
|
| Pragmatic Clinical Trials as Topic | 4 | 2022 | 65 | 0.510 |
Why?
|
| Incidence | 7 | 2026 | 1278 | 0.500 |
Why?
|
| Sepsis | 2 | 2016 | 64 | 0.500 |
Why?
|
| Lung Transplantation | 4 | 2009 | 7 | 0.500 |
Why?
|
| Registries | 6 | 2019 | 475 | 0.500 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 3 | 0.490 |
Why?
|
| Neuroimaging | 1 | 2016 | 6 | 0.480 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 20 | 0.480 |
Why?
|
| Logistic Models | 9 | 2017 | 866 | 0.470 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2013 | 2 | 0.460 |
Why?
|
| Attitude of Health Personnel | 4 | 2025 | 204 | 0.450 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 107 | 0.450 |
Why?
|
| Biomedical Research | 4 | 2020 | 77 | 0.440 |
Why?
|
| Primary Health Care | 4 | 2017 | 729 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 368 | 0.430 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 4 | 0.420 |
Why?
|
| Hospitals, Veterans | 4 | 2014 | 31 | 0.420 |
Why?
|
| Quality Indicators, Health Care | 2 | 2014 | 124 | 0.410 |
Why?
|
| Motor Activity | 2 | 2015 | 207 | 0.400 |
Why?
|
| Ambulatory Care | 1 | 2015 | 228 | 0.400 |
Why?
|
| Health Maintenance Organizations | 1 | 2015 | 403 | 0.400 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 2 | 0.390 |
Why?
|
| Physicians, Primary Care | 1 | 2013 | 63 | 0.380 |
Why?
|
| Thoracic Diseases | 1 | 2012 | 2 | 0.380 |
Why?
|
| Age Factors | 8 | 2020 | 874 | 0.380 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 6 | 0.380 |
Why?
|
| Pattern Recognition, Automated | 1 | 2012 | 1 | 0.380 |
Why?
|
| Drug Costs | 2 | 2014 | 32 | 0.380 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 7 | 0.370 |
Why?
|
| Medical Oncology | 2 | 2023 | 33 | 0.370 |
Why?
|
| Biopsy | 4 | 2016 | 80 | 0.370 |
Why?
|
| Delivery of Health Care | 6 | 2022 | 383 | 0.370 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 16 | 0.360 |
Why?
|
| Cause of Death | 2 | 2015 | 179 | 0.360 |
Why?
|
| Withholding Treatment | 1 | 2011 | 26 | 0.350 |
Why?
|
| Respiration, Artificial | 4 | 2023 | 38 | 0.350 |
Why?
|
| Acute Disease | 5 | 2017 | 147 | 0.350 |
Why?
|
| Biopsy, Needle | 6 | 2013 | 14 | 0.350 |
Why?
|
| Young Adult | 7 | 2024 | 2538 | 0.350 |
Why?
|
| Asthma | 3 | 2007 | 401 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2022 | 323 | 0.350 |
Why?
|
| Sex Factors | 7 | 2016 | 599 | 0.340 |
Why?
|
| Thromboembolism | 2 | 2014 | 32 | 0.340 |
Why?
|
| Health Status | 4 | 2016 | 291 | 0.340 |
Why?
|
| Chronic Disease | 5 | 2022 | 398 | 0.340 |
Why?
|
| Odds Ratio | 5 | 2015 | 631 | 0.340 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 527 | 0.340 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 80 | 0.340 |
Why?
|
| Attitude to Health | 4 | 2012 | 147 | 0.330 |
Why?
|
| Research Design | 9 | 2020 | 337 | 0.330 |
Why?
|
| Antiviral Agents | 2 | 2009 | 85 | 0.330 |
Why?
|
| Patient Care Team | 3 | 2016 | 107 | 0.320 |
Why?
|
| Health Priorities | 2 | 2020 | 24 | 0.320 |
Why?
|
| Models, Biological | 2 | 2007 | 27 | 0.320 |
Why?
|
| Anxiety | 4 | 2022 | 162 | 0.320 |
Why?
|
| Adolescent | 10 | 2024 | 3625 | 0.320 |
Why?
|
| Mediastinoscopy | 4 | 2017 | 5 | 0.320 |
Why?
|
| Medical Audit | 2 | 2016 | 32 | 0.320 |
Why?
|
| National Health Programs | 1 | 2009 | 12 | 0.310 |
Why?
|
| Neuraminidase | 1 | 2009 | 1 | 0.310 |
Why?
|
| Zanamivir | 1 | 2009 | 1 | 0.310 |
Why?
|
| Oseltamivir | 1 | 2009 | 3 | 0.310 |
Why?
|
| Survival Analysis | 6 | 2017 | 197 | 0.300 |
Why?
|
| Disease Outbreaks | 1 | 2009 | 37 | 0.300 |
Why?
|
| Disease Progression | 8 | 2019 | 266 | 0.290 |
Why?
|
| Health Care Costs | 2 | 2009 | 211 | 0.290 |
Why?
|
| Liver Diseases | 2 | 2024 | 23 | 0.290 |
Why?
|
| ROC Curve | 5 | 2017 | 73 | 0.280 |
Why?
|
| Quality Improvement | 4 | 2020 | 189 | 0.280 |
Why?
|
| Mentoring | 2 | 2019 | 29 | 0.280 |
Why?
|
| Survivors | 2 | 2022 | 157 | 0.280 |
Why?
|
| Pulmonary Artery | 1 | 2008 | 2 | 0.280 |
Why?
|
| Respiration | 1 | 2008 | 6 | 0.280 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2007 | 1 | 0.270 |
Why?
|
| Respiratory Insufficiency | 2 | 2023 | 16 | 0.270 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 95 | 0.260 |
Why?
|
| Research | 3 | 2023 | 60 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 25 | 0.260 |
Why?
|
| Professional-Patient Relations | 2 | 2017 | 48 | 0.260 |
Why?
|
| Postoperative Hemorrhage | 2 | 2017 | 8 | 0.260 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 55 | 0.260 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2007 | 88 | 0.260 |
Why?
|
| Walking | 3 | 2019 | 89 | 0.250 |
Why?
|
| Research Report | 2 | 2020 | 23 | 0.250 |
Why?
|
| Combined Modality Therapy | 3 | 2013 | 114 | 0.250 |
Why?
|
| Qualitative Research | 3 | 2023 | 290 | 0.250 |
Why?
|
| Pneumonectomy | 2 | 2016 | 6 | 0.250 |
Why?
|
| Socioeconomic Factors | 4 | 2026 | 603 | 0.250 |
Why?
|
| Culture | 2 | 2016 | 30 | 0.250 |
Why?
|
| Oxyhemoglobins | 1 | 2005 | 1 | 0.240 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 168 | 0.240 |
Why?
|
| Pyridones | 1 | 2005 | 7 | 0.230 |
Why?
|
| Influenza, Human | 1 | 2009 | 294 | 0.230 |
Why?
|
| Sickness Impact Profile | 2 | 2005 | 25 | 0.230 |
Why?
|
| Cough | 2 | 2015 | 20 | 0.230 |
Why?
|
| Social Determinants of Health | 1 | 2026 | 39 | 0.230 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 64 | 0.220 |
Why?
|
| Preventive Health Services | 2 | 2017 | 147 | 0.220 |
Why?
|
| Dalteparin | 2 | 2014 | 2 | 0.220 |
Why?
|
| Epoprostenol | 1 | 2004 | 1 | 0.220 |
Why?
|
| American Cancer Society | 1 | 2024 | 12 | 0.220 |
Why?
|
| Stroke | 3 | 2016 | 309 | 0.220 |
Why?
|
| Platelet Count | 1 | 2024 | 9 | 0.210 |
Why?
|
| Enteral Nutrition | 1 | 2004 | 5 | 0.210 |
Why?
|
| Observational Studies as Topic | 2 | 2022 | 46 | 0.210 |
Why?
|
| Veterans Health | 2 | 2014 | 16 | 0.210 |
Why?
|
| Judgment | 1 | 2024 | 3 | 0.210 |
Why?
|
| Mammography | 2 | 2015 | 173 | 0.210 |
Why?
|
| Cancer Survivors | 1 | 2025 | 115 | 0.200 |
Why?
|
| Nephrectomy | 1 | 2023 | 5 | 0.200 |
Why?
|
| Child | 5 | 2024 | 2485 | 0.200 |
Why?
|
| Noninvasive Ventilation | 1 | 2023 | 11 | 0.190 |
Why?
|
| Hospital Costs | 3 | 2014 | 37 | 0.190 |
Why?
|
| Cross Infection | 1 | 2003 | 24 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 163 | 0.190 |
Why?
|
| Medical Records | 3 | 2015 | 91 | 0.190 |
Why?
|
| Dexamethasone | 1 | 2022 | 11 | 0.190 |
Why?
|
| Managed Care Programs | 2 | 2015 | 300 | 0.190 |
Why?
|
| Spinal Cord Injuries | 1 | 2002 | 4 | 0.190 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 702 | 0.190 |
Why?
|
| Patient Education as Topic | 2 | 2022 | 193 | 0.190 |
Why?
|
| Policy | 1 | 2022 | 20 | 0.180 |
Why?
|
| Ventilators, Mechanical | 1 | 2002 | 1 | 0.180 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 5 | 0.180 |
Why?
|
| Radiography | 4 | 2015 | 36 | 0.180 |
Why?
|
| Needs Assessment | 1 | 2002 | 66 | 0.180 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 380 | 0.180 |
Why?
|
| Respiratory Function Tests | 3 | 2013 | 31 | 0.180 |
Why?
|
| Health Services Research | 3 | 2022 | 201 | 0.180 |
Why?
|
| Smoking Cessation | 3 | 2017 | 149 | 0.180 |
Why?
|
| Urologic Surgical Procedures | 3 | 2017 | 6 | 0.180 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 1295 | 0.170 |
Why?
|
| Inpatients | 2 | 2020 | 78 | 0.170 |
Why?
|
| Women's Health | 1 | 2002 | 198 | 0.170 |
Why?
|
| Immunologic Factors | 2 | 2019 | 35 | 0.170 |
Why?
|
| Exercise Test | 2 | 2015 | 41 | 0.170 |
Why?
|
| Glucose-6-Phosphate | 1 | 2001 | 1 | 0.170 |
Why?
|
| Aging | 1 | 2002 | 159 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2000 | 6 | 0.170 |
Why?
|
| Canada | 3 | 2017 | 54 | 0.170 |
Why?
|
| Calcium Channel Blockers | 1 | 2020 | 15 | 0.170 |
Why?
|
| Confidence Intervals | 3 | 2008 | 228 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2000 | 1 | 0.170 |
Why?
|
| Counseling | 1 | 2022 | 173 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2000 | 18 | 0.160 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 208 | 0.160 |
Why?
|
| Patient Portals | 1 | 2021 | 23 | 0.160 |
Why?
|
| Early Medical Intervention | 1 | 2020 | 11 | 0.160 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 686 | 0.160 |
Why?
|
| Government Programs | 1 | 2020 | 11 | 0.160 |
Why?
|
| Medicare | 3 | 2022 | 197 | 0.160 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 2 | 0.160 |
Why?
|
| Cephalosporins | 1 | 2020 | 6 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 28 | 0.160 |
Why?
|
| Models, Statistical | 2 | 2020 | 171 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 53 | 0.160 |
Why?
|
| Likelihood Functions | 2 | 2012 | 45 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 84 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 43 | 0.160 |
Why?
|
| Genes, cdc | 1 | 2019 | 1 | 0.150 |
Why?
|
| Income | 2 | 2017 | 86 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2022 | 276 | 0.150 |
Why?
|
| Editorial Policies | 1 | 2019 | 5 | 0.150 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 15 | 0.150 |
Why?
|
| Sex Distribution | 3 | 2015 | 174 | 0.150 |
Why?
|
| Age Distribution | 3 | 2015 | 230 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 1 | 1998 | 31 | 0.140 |
Why?
|
| Bronchodilator Agents | 2 | 2015 | 22 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2016 | 210 | 0.140 |
Why?
|
| Disease Management | 2 | 2016 | 110 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2018 | 25 | 0.140 |
Why?
|
| Thrombosis | 2 | 2012 | 14 | 0.140 |
Why?
|
| Quality-Adjusted Life Years | 4 | 2014 | 41 | 0.140 |
Why?
|
| Simulation Training | 1 | 2017 | 1 | 0.130 |
Why?
|
| Multilevel Analysis | 1 | 2017 | 11 | 0.130 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1997 | 1 | 0.130 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2017 | 9 | 0.130 |
Why?
|
| Tobacco Use Disorder | 1 | 2017 | 35 | 0.130 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 10 | 0.130 |
Why?
|
| Efficiency, Organizational | 1 | 2017 | 26 | 0.130 |
Why?
|
| Communication | 2 | 2023 | 181 | 0.130 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2017 | 27 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 7 | 0.130 |
Why?
|
| Patient Care | 1 | 2017 | 30 | 0.130 |
Why?
|
| Data Collection | 5 | 2013 | 234 | 0.130 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 17 | 0.130 |
Why?
|
| Urologic Diseases | 1 | 2017 | 7 | 0.130 |
Why?
|
| Pulmonologists | 1 | 2017 | 1 | 0.130 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1997 | 1 | 0.130 |
Why?
|
| Students, Medical | 1 | 2017 | 34 | 0.130 |
Why?
|
| Hypoxia | 1 | 1997 | 8 | 0.130 |
Why?
|
| Respiratory Distress Syndrome, Adult | 1 | 1997 | 9 | 0.130 |
Why?
|
| Oncologists | 1 | 2016 | 7 | 0.130 |
Why?
|
| Aspirin | 1 | 2017 | 63 | 0.130 |
Why?
|
| Sleep Medicine Specialty | 1 | 2016 | 5 | 0.130 |
Why?
|
| Asia | 1 | 2016 | 12 | 0.130 |
Why?
|
| Length of Stay | 2 | 2010 | 182 | 0.130 |
Why?
|
| False Positive Reactions | 1 | 2016 | 26 | 0.120 |
Why?
|
| Palliative Care | 1 | 2017 | 54 | 0.120 |
Why?
|
| Learning | 1 | 2016 | 18 | 0.120 |
Why?
|
| Translational Medical Research | 1 | 2016 | 32 | 0.120 |
Why?
|
| Preoperative Care | 1 | 2016 | 20 | 0.120 |
Why?
|
| Hospitals, Community | 1 | 2016 | 23 | 0.120 |
Why?
|
| Advisory Committees | 1 | 2017 | 112 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 214 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 32 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2016 | 31 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2016 | 18 | 0.120 |
Why?
|
| Health Resources | 1 | 2016 | 39 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 10 | 0.120 |
Why?
|
| Mid-Atlantic Region | 1 | 2015 | 6 | 0.120 |
Why?
|
| Hypertension | 1 | 2020 | 486 | 0.120 |
Why?
|
| Sampling Studies | 1 | 2015 | 43 | 0.120 |
Why?
|
| Pediatrics | 1 | 2017 | 149 | 0.120 |
Why?
|
| Northwestern United States | 1 | 2015 | 53 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 50 | 0.120 |
Why?
|
| Florida | 2 | 2026 | 7 | 0.120 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 642 | 0.120 |
Why?
|
| Habits | 1 | 2015 | 6 | 0.120 |
Why?
|
| Somatoform Disorders | 1 | 2015 | 6 | 0.110 |
Why?
|
| Tics | 1 | 2015 | 3 | 0.110 |
Why?
|
| Ethnic Groups | 2 | 2016 | 443 | 0.110 |
Why?
|
| Focus Groups | 4 | 2016 | 144 | 0.110 |
Why?
|
| Recurrence | 3 | 2000 | 166 | 0.110 |
Why?
|
| Health Status Indicators | 2 | 2005 | 60 | 0.110 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 104 | 0.110 |
Why?
|
| Consensus | 3 | 2020 | 41 | 0.110 |
Why?
|
| Papillomaviridae | 2 | 2025 | 61 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2016 | 141 | 0.110 |
Why?
|
| Infant | 2 | 2016 | 1228 | 0.110 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 121 | 0.110 |
Why?
|
| Internet | 1 | 2016 | 207 | 0.110 |
Why?
|
| Insurance Coverage | 2 | 2016 | 99 | 0.110 |
Why?
|
| Health Facilities | 1 | 2014 | 16 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2014 | 269 | 0.100 |
Why?
|
| Drug Administration Schedule | 3 | 2012 | 99 | 0.100 |
Why?
|
| Reproducibility of Results | 5 | 2008 | 363 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2014 | 72 | 0.100 |
Why?
|
| Biomarkers | 3 | 2012 | 302 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 190 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2014 | 129 | 0.100 |
Why?
|
| National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division | 1 | 2013 | 4 | 0.100 |
Why?
|
| Physical Examination | 1 | 2013 | 20 | 0.100 |
Why?
|
| Insurance, Health | 2 | 2014 | 169 | 0.100 |
Why?
|
| Medical History Taking | 1 | 2013 | 33 | 0.100 |
Why?
|
| Anti-Infective Agents | 2 | 2003 | 13 | 0.100 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 14 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 19 | 0.100 |
Why?
|
| Exercise | 1 | 2018 | 538 | 0.100 |
Why?
|
| Telemedicine | 1 | 2016 | 196 | 0.100 |
Why?
|
| Policy Making | 1 | 2012 | 13 | 0.100 |
Why?
|
| Patient Preference | 1 | 2013 | 49 | 0.100 |
Why?
|
| APACHE | 1 | 2012 | 11 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2012 | 50 | 0.090 |
Why?
|
| Stockings, Compression | 1 | 2012 | 1 | 0.090 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2012 | 2 | 0.090 |
Why?
|
| Aminoglycosides | 2 | 2003 | 3 | 0.090 |
Why?
|
| Fluoroquinolones | 2 | 2003 | 5 | 0.090 |
Why?
|
| Hispanic Americans | 2 | 2012 | 370 | 0.090 |
Why?
|
| Health Services Misuse | 1 | 2011 | 12 | 0.090 |
Why?
|
| Censuses | 1 | 2012 | 28 | 0.090 |
Why?
|
| Prevalence | 4 | 2015 | 830 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 29 | 0.090 |
Why?
|
| South Carolina | 2 | 2025 | 17 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 168 | 0.090 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2010 | 82 | 0.080 |
Why?
|
| Personality Tests | 1 | 1990 | 1 | 0.080 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2010 | 2 | 0.080 |
Why?
|
| Cross-Cultural Comparison | 1 | 1990 | 11 | 0.080 |
Why?
|
| Risk Adjustment | 1 | 2010 | 19 | 0.080 |
Why?
|
| Child Behavior Disorders | 1 | 1990 | 17 | 0.080 |
Why?
|
| Risk | 3 | 2012 | 492 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 7 | 0.080 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2009 | 2 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 3 | 0.080 |
Why?
|
| International Cooperation | 1 | 2009 | 14 | 0.080 |
Why?
|
| Nausea | 1 | 2009 | 6 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2009 | 5 | 0.080 |
Why?
|
| Vomiting | 1 | 2009 | 11 | 0.080 |
Why?
|
| Influenza A virus | 1 | 2009 | 13 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 248 | 0.080 |
Why?
|
| Health Care Rationing | 1 | 2009 | 11 | 0.080 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 70 | 0.080 |
Why?
|
| Acute Lung Injury | 1 | 2009 | 3 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2009 | 23 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 35 | 0.070 |
Why?
|
| Thoracoscopy | 1 | 2008 | 2 | 0.070 |
Why?
|
| Genome | 1 | 2008 | 4 | 0.070 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2008 | 9 | 0.070 |
Why?
|
| Rats | 1 | 2008 | 33 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 23 | 0.070 |
Why?
|
| Waiting Lists | 2 | 2009 | 12 | 0.070 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2008 | 1 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2008 | 30 | 0.070 |
Why?
|
| Life Expectancy | 2 | 2017 | 29 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2008 | 8 | 0.070 |
Why?
|
| Reference Standards | 2 | 2006 | 14 | 0.070 |
Why?
|
| Forced Expiratory Volume | 1 | 2008 | 66 | 0.070 |
Why?
|
| Genomics | 1 | 2008 | 56 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Omalizumab | 1 | 2007 | 4 | 0.070 |
Why?
|
| Genetic Counseling | 2 | 1999 | 27 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 122 | 0.070 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2007 | 2 | 0.070 |
Why?
|
| Inflammation | 1 | 2008 | 60 | 0.070 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 3 | 0.060 |
Why?
|
| Carcinoid Tumor | 1 | 1986 | 1 | 0.060 |
Why?
|
| Abdominal Neoplasms | 1 | 1986 | 2 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 45 | 0.060 |
Why?
|
| Calcaneus | 1 | 2006 | 5 | 0.060 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2006 | 20 | 0.060 |
Why?
|
| Physicians | 2 | 2016 | 120 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2015 | 959 | 0.060 |
Why?
|
| Hospitals, University | 1 | 2005 | 14 | 0.060 |
Why?
|
| Social Support | 2 | 2019 | 215 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 262 | 0.060 |
Why?
|
| Phenotype | 1 | 2026 | 154 | 0.060 |
Why?
|
| Osteoporosis | 1 | 2006 | 75 | 0.060 |
Why?
|
| Polysaccharides | 2 | 2017 | 3 | 0.060 |
Why?
|
| Heart-Lung Transplantation | 1 | 2005 | 2 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2005 | 15 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 2 | 2020 | 69 | 0.050 |
Why?
|
| Papanicolaou Test | 1 | 2024 | 38 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2024 | 48 | 0.050 |
Why?
|
| Airway Obstruction | 1 | 2004 | 4 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1107 | 0.050 |
Why?
|
| Perception | 1 | 2024 | 56 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2004 | 12 | 0.050 |
Why?
|
| Dyspnea | 1 | 2004 | 45 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 120 | 0.050 |
Why?
|
| Australia | 2 | 2014 | 26 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 27 | 0.050 |
Why?
|
| Occult Blood | 2 | 2021 | 162 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 15 | 0.050 |
Why?
|
| Embolism, Air | 1 | 2003 | 1 | 0.050 |
Why?
|
| Arteries | 1 | 2003 | 8 | 0.050 |
Why?
|
| Penicillanic Acid | 1 | 2003 | 1 | 0.050 |
Why?
|
| Piperacillin | 1 | 2003 | 1 | 0.050 |
Why?
|
| Linear Models | 3 | 2010 | 204 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2022 | 8 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 164 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2022 | 87 | 0.050 |
Why?
|
| Ontario | 1 | 2002 | 20 | 0.050 |
Why?
|
| Sexuality | 1 | 2002 | 11 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 59 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2002 | 79 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 60 | 0.040 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 73 | 0.040 |
Why?
|
| Inhalation Exposure | 1 | 2001 | 5 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2001 | 38 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2001 | 23 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2001 | 66 | 0.040 |
Why?
|
| beta-Lactams | 1 | 2000 | 1 | 0.040 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2000 | 2 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2000 | 16 | 0.040 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2000 | 4 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2000 | 6 | 0.040 |
Why?
|
| Patient Participation | 1 | 2022 | 124 | 0.040 |
Why?
|
| Education | 1 | 2020 | 14 | 0.040 |
Why?
|
| Health Policy | 2 | 2015 | 106 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2020 | 4 | 0.040 |
Why?
|
| Pedigree | 2 | 1999 | 65 | 0.040 |
Why?
|
| Pregnancy | 3 | 2000 | 1565 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2000 | 73 | 0.040 |
Why?
|
| Organizational Objectives | 1 | 2019 | 14 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 33 | 0.040 |
Why?
|
| Thoracotomy | 1 | 1999 | 1 | 0.040 |
Why?
|
| Fees and Charges | 1 | 1999 | 4 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 1999 | 137 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 1999 | 144 | 0.040 |
Why?
|
| Family Practice | 1 | 1999 | 41 | 0.040 |
Why?
|
| Obstetrics | 1 | 1999 | 20 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 1999 | 67 | 0.040 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 1998 | 5 | 0.040 |
Why?
|
| Mortality | 2 | 2016 | 116 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 1998 | 25 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 1 | 0.030 |
Why?
|
| Receptors, Angiotensin | 1 | 1997 | 3 | 0.030 |
Why?
|
| Psychometrics | 2 | 2005 | 119 | 0.030 |
Why?
|
| Albuminuria | 1 | 1997 | 39 | 0.030 |
Why?
|
| Enoxaparin | 1 | 2017 | 1 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 1 | 2017 | 10 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 1997 | 35 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1997 | 4 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1999 | 269 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 12 | 0.030 |
Why?
|
| Health Promotion | 2 | 2016 | 293 | 0.030 |
Why?
|
| Warfarin | 1 | 2017 | 72 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 214 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2012 | 1455 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 268 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 19 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2016 | 29 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 36 | 0.030 |
Why?
|
| Minority Groups | 2 | 2013 | 104 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 36 | 0.030 |
Why?
|
| Health Education | 1 | 2016 | 82 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 1995 | 3 | 0.030 |
Why?
|
| Immunotherapy | 1 | 1995 | 7 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1995 | 9 | 0.030 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 1995 | 15 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 59 | 0.030 |
Why?
|
| Syndrome | 1 | 2015 | 28 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 69 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 27 | 0.030 |
Why?
|
| Saudi Arabia | 1 | 2014 | 1 | 0.030 |
Why?
|
| Brazil | 1 | 2014 | 10 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 61 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 28 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cost Savings | 1 | 2014 | 20 | 0.030 |
Why?
|
| North America | 1 | 2014 | 31 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 112 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 39 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2016 | 288 | 0.030 |
Why?
|
| Health Services | 1 | 2014 | 110 | 0.030 |
Why?
|
| Suicide | 1 | 1994 | 116 | 0.020 |
Why?
|
| Uncertainty | 1 | 2012 | 5 | 0.020 |
Why?
|
| Grounded Theory | 1 | 2012 | 7 | 0.020 |
Why?
|
| Fear | 1 | 2012 | 14 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 9 | 0.020 |
Why?
|
| Dementia | 1 | 1994 | 136 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2012 | 22 | 0.020 |
Why?
|
| Vitamin K | 1 | 2012 | 14 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 21 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 2012 | 6 | 0.020 |
Why?
|
| African Americans | 1 | 1994 | 429 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 84 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2012 | 102 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 12 | 0.020 |
Why?
|
| Markov Chains | 1 | 2011 | 22 | 0.020 |
Why?
|
| Family Characteristics | 1 | 2012 | 70 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 35 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 177 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2012 | 140 | 0.020 |
Why?
|
| Alcoholism | 1 | 1994 | 333 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1997 | 689 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2010 | 41 | 0.020 |
Why?
|
| Personality Disorders | 1 | 1990 | 1 | 0.020 |
Why?
|
| Multi-Institutional Systems | 1 | 2010 | 2 | 0.020 |
Why?
|
| Puerto Rico | 1 | 1990 | 5 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 171 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1990 | 107 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2010 | 92 | 0.020 |
Why?
|
| HIV Infections | 1 | 1995 | 584 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2009 | 3 | 0.020 |
Why?
|
| Isoniazid | 1 | 2009 | 3 | 0.020 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2009 | 5 | 0.020 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 10 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 256 | 0.020 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2009 | 5 | 0.020 |
Why?
|
| Medicaid | 1 | 2010 | 188 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2008 | 1 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 2 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 18 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2008 | 3 | 0.020 |
Why?
|
| Diagnostic Techniques, Respiratory System | 1 | 2007 | 4 | 0.020 |
Why?
|
| Animals | 1 | 2008 | 285 | 0.020 |
Why?
|
| Sweden | 1 | 2007 | 19 | 0.020 |
Why?
|
| Anal Canal | 1 | 2006 | 9 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2006 | 45 | 0.020 |
Why?
|
| Age of Onset | 1 | 2006 | 74 | 0.020 |
Why?
|
| Hip | 1 | 2006 | 9 | 0.020 |
Why?
|
| Spine | 1 | 2006 | 8 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2006 | 34 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2006 | 54 | 0.020 |
Why?
|
| Bias | 1 | 2006 | 95 | 0.010 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2005 | 2 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 52 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 65 | 0.010 |
Why?
|
| Direct Service Costs | 1 | 2003 | 8 | 0.010 |
Why?
|
| Forecasting | 1 | 2004 | 68 | 0.010 |
Why?
|
| Drug Compounding | 1 | 2003 | 5 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 65 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2004 | 265 | 0.010 |
Why?
|
| London | 1 | 1999 | 6 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 1999 | 4 | 0.010 |
Why?
|
| Maternal Age | 1 | 1999 | 74 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 61 | 0.010 |
Why?
|
| Genotype | 1 | 1997 | 224 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1995 | 4 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1995 | 3 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 17 | 0.010 |
Why?
|
| Eosinophils | 1 | 1995 | 10 | 0.010 |
Why?
|
| Prenatal Care | 1 | 1996 | 129 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 28 | 0.010 |
Why?
|
| Demography | 1 | 1994 | 92 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 1994 | 123 | 0.010 |
Why?
|
| European Continental Ancestry Group | 1 | 1994 | 470 | 0.010 |
Why?
|